These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6861845)

  • 1. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.
    Bogers WA; Meems L
    Eur J Clin Pharmacol; 1983; 24(3):301-5. PubMed ID: 6861845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endralazine, a new peripheral vasodilator--a randomized cross-over trial against dihydralazine.
    Kirch W; Axthelm T
    J Cardiovasc Pharmacol; 1982; 4(4):562-6. PubMed ID: 6181329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
    Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL
    Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
    Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
    Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of once daily endralazine in hypertension.
    Wu R; Spence JD; Carruthers SG
    Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure.
    Quyyumi AA; Wagstaff D; Evans TR
    Am J Cardiol; 1983 May; 51(8):1353-7. PubMed ID: 6846162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.
    Seedat YK; Rawat R
    S Afr Med J; 1984 Nov; 66(18):682-4. PubMed ID: 6387966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
    Chazan BI; Duff DA; McCallum A; Whaley K
    Curr Med Res Opin; 1986; 10(3):150-8. PubMed ID: 2873966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine.
    Elliott HL; Meredith PA; Reid JL
    J Hypertens Suppl; 1984 Dec; 2(3):S551-4. PubMed ID: 6599716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacological studies with the vasodilator endralazine in normotensive subjects and essential hypertensives.
    Elliott HL; Meredith PA; Howden CW; Lawrie CB; Reid JL
    Int J Clin Pharmacol Res; 1984; 4(1):61-9. PubMed ID: 6469433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.
    Karlberg BE; Larsson R; Ohman KP; Norlander B; Wirsen A; Hed J; Lundh BL; Flock A
    Eur J Clin Pharmacol; 1983; 25(2):179-86. PubMed ID: 6138257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antihypertensive pharmacotherapy with the vasodilators captopril and endralazine].
    Hartmann HG; Schumacher H
    Schweiz Med Wochenschr; 1985 Jul; 115(27-28):939-44. PubMed ID: 2862703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs.
    Salzmann R; Gerber W; Pally C; Scholtysik G
    J Pharm Pharmacol; 1983 May; 35(5):293-8. PubMed ID: 6134797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the vasodilator MDL-899 in patients with essential hypertension.
    Elliott HL; Campbell L; Sumner DJ; Reid JL
    J Cardiovasc Pharmacol; 1985; 7(5):948-52. PubMed ID: 2413306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.
    Lüscher T; Havelka J; Greminger P; Tuma J; Täuber M; Siegenthaler W; Vetter W
    Eur J Clin Pharmacol; 1982; 23(5):411-5. PubMed ID: 6129980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension.
    Kingswood JC; Harrison PR; Banks RA; Higgs E; Mackenzie JC
    Postgrad Med J; 1983; 59 Suppl 3():173-6. PubMed ID: 6647204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
    van Brummelen P; Bühler FR; Kiowski W; Bolli P; Bertel O
    Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):380-5. PubMed ID: 40887
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile.
    Hauger-Klevene JH; Reader C; Mayer E; Sanchez MR
    Int J Clin Pharmacol Res; 1986; 6(4):275-81. PubMed ID: 3531038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of treatment-resistant hypertension: comparison of the antihypertensive effect of endralazine and minoxidil (author's transl)].
    Kindler J; Glöckner WM; Sieberth HG; Konrads A; Meurer KA; Schulz V; Vaith P
    Dtsch Med Wochenschr; 1981 Sep; 106(37):1176-81. PubMed ID: 7343274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.